Fox Run Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Fox Run Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-35,656	Closed	-$536K	–	1185
2025 Q2	$536K	Buy	35,656 +24,839	+230%	+$355K	0.09%	442
2025 Q1	$143K	Buy	+10,817	New	+$149K	0.02%	837
2018 Q3	–	Sell	-115,450	Closed	-$743K	–	781
2018 Q2	$743K	Buy	115,450 +76,640	+197%	+$483K	0.24%	119
2018 Q1	$254K	Buy	+38,810	New	+$272K	0.06%	551
2017 Q2	–	Sell	-27,500	Closed	-$221K	–	789
2017 Q1	$221K	Sell	27,500 -11,000	-29%	-$95K	0.09%	464
2016 Q4	$349K	Buy	+38,500	New	+$358K	0.18%	242
2016 Q2	–	Sell	-54,500	Closed	-$493K	–	648
2016 Q1	$493K	Buy	+54,500	New	+$487K	0.33%	85

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fox Run Management's RDY Position: Q3 2025 in Review

Fox Run Management sold out of Dr. Reddy's Laboratories (RDY) in Q3 2025, closing a stake of 35,656 shares — an estimated $536K sold.

Fox Run Management first reported a position in RDY in Q1 2016 and held it in 7 quarters. The position peaked at $743K in Q2 2018. 228 funds tracked by Wall St. Rank hold RDY as of Q3 2025.

Fox Run Management reported no remaining Dr. Reddy's Laboratories position as of Q3 2025 after selling out during the quarter.
Fox Run Management sold 35,656 Dr. Reddy's Laboratories shares in Q3 2025, an estimated $536K.
Fox Run Management first reported a position in Dr. Reddy's Laboratories in Q1 2016 and held it in 7 quarters.
Fox Run Management's Dr. Reddy's Laboratories position peaked at $743K in Q2 2018.
228 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.